Search This Blog

Thursday, May 28, 2015

U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen® (NYSE:LLY)

Marks approval of first concentrated mealtime insulin analog in the U.S. and expands Lilly's portfolio of medicines for people with type 1 and type 2 diabetes



U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen® (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.